Trial Profile
OX-04-038 Multicenter Phase II Trial of Oxaliplatin plus Permetrexed for Second-line Chemotherapy of Metastatic or Locally Advanced Non-Small Cell Lung Cancer.
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2011
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jul 2009 New trial record.